Finance

Lists
ZNTL:NASDAQ
Zentalis Pharmaceuticals Inc
$1.70
+1.19%
(+0.020) 1D
$1.71
+0.40% (+0.0068)
After hours
Closed: Nov 13, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZNTL...
Open
$1.68
High
$1.76
Low
$1.63
Mkt. cap
167.05M
Avg. vol.
1.38M
Volume
1.30M
52-wk high
$6.95
52-wk low
$1.28
EPS
-$1.93
Beta
1.91
Shares outstanding
98.27M
No. of employees
106
Open
$1.68
High
$1.76
Low
$1.63
Mkt. cap
167.05M
Avg. vol.
1.38M
Volume
1.30M
52-wk high
$6.95
52-wk low
$1.28
EPS
-$1.93
Beta
1.91
Shares outstanding
98.27M
No. of employees
106
News stories
From web sources and news partners
About Zentalis Pharmaceuticals Inc
CEO-
Employees106
Founded2014
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitezentalis.com
Analyst ratings
Based on 7 analysts giving stock ratings to ZNTL in the past 3 months
Buy
Buy
5
Hold
2
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for ZNTL in the last 3 months.
Highest
Current $1.70
$10.00 (+488.24%)
Average
$6.83 (+301.76%)
Lowest
$5.00 (+194.12%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yanan Zhu
Wells Fargo
Hold
Maintained
$5.00
+194.1%
11/11/2026
Robert Driscoll
Wedbush
Buy
Upgraded
$6.00
+252.9%
11/10/2026
Michael Ulz
Morgan Stanley
Hold
Reiterated
$5.00
+194.1%
11/10/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
$10.00
+488.2%
11/10/2026
Graig Suvannavejh
Mizuho Securities
Buy
Maintained
$7.00
+311.8%
10/29/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
10/19/2026
Unknown Analyst
Leerink Partners
Buy
Upgraded
$8.00
+370.6%
10/05/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$10.00
+488.2%
08/07/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
08/06/2026
Michael King
Rodman & Renshaw
Buy
Initiated
$11.00
+547.1%
07/23/2026
Jay Olson
Oppenheimer
Buy
Initiated
$9.00
+429.4%
06/15/2026
Unknown Analyst
Wedbush
Hold
Maintained
$4.00
+135.3%
05/13/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$9.00
+429.4%
05/13/2026
Eva Fortea Verdejo
Wells Fargo
Hold
Reiterated
$5.00
+194.1%
05/13/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
30.69M
28.72M
35.16M
22.33M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.77M
9.14M
9.23M
8.82M
Operating expense
34.46M
37.86M
44.39M
31.15M
Total operating expenses
34.46M
37.86M
44.39M
31.15M
Operating income
-34.46M
-37.86M
-44.39M
-31.15M
Other non operating income
-
-
-
-
EBT including unusual items
-34.77M
-35.23M
-42.15M
-28.70M
EBT excluding unusual items
-34.12M
-35.23M
-42.15M
-28.70M
Income tax expense
442.00K
120.00K
138.00K
118.00K
Effective tax rate
-1.27%
-0.34%
-0.33%
-0.41%
Other operating expenses
-
-
-
-
Net income
-35.22M
-35.35M
-42.29M
-28.82M
Net profit margin
-
-
-
-
Earnings per share
-0.49
-0.50
-0.59
-0.34
Interest and investment income
338.00K
2.62M
2.24M
2.46M
Interest expense
-
-
-
-
Net interest expenses
338.00K
2.62M
2.24M
2.46M
Depreciation and amortization charges
-
-
-
-
EBITDA
-34.30M
-37.70M
-44.24M
-31.00M
Gain or loss from assets sale
-26.00K
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps